Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Biotransformation: Overview01:16

Drug Biotransformation: Overview

2.4K
Pharmaceutical substances known as xenobiotics are predominantly lipophilic and nonionized. This enables them to permeate lipid bilayers, such as cell membranes, and interact with intracellular target receptors. Lipophilic drugs have an advantage in crossing biological barriers and reaching their intended sites of action. However, lipophilic drugs often have a restricted capacity for renal expulsion or elimination from the body. When these drugs enter the kidneys and undergo glomerular...
2.4K
Drug Absorption: Overview01:17

Drug Absorption: Overview

572
The process of drug absorption signifies the transition of a drug from its site of administration into the plasma. This process is influenced by various factors, including the route of administration, the anatomy of the absorption site, the mechanism of absorption, gut motility, and the drug's physicochemical properties.
When drugs are injected intravenously, they directly enter the systemic circulation. Alternatively, orally administered drugs navigate through the gastrointestinal (GI)...
572
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

316
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
316
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

157
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
157
Drugs for Treatment of Constipation-Predominant IBS01:21

Drugs for Treatment of Constipation-Predominant IBS

155
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
155
Biopharmaceutics and Pharmacokinetics: Overview01:28

Biopharmaceutics and Pharmacokinetics: Overview

2.0K
Understanding drugs, drug products, and their performance in pharmaceutical science is pivotal. Drugs, whether simple molecules or complex compounds, are designed to interact with the body's biological systems to diagnose, treat, or prevent diseases. Drug products include various delivery systems such as tablets, capsules, injections, and inhalers. The performance of these drug products is gauged by their ability to deliver the active ingredient to the desired site of action at the...
2.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pseudomonal sternal abscess and osteomyelitis as an initial manifestation of common variable immunodeficiency.

ASM case reports·2026
Same author

Distinct molecular epidemiology and outcomes of carbapenem-resistant gram-negative infections in Lebanon: insights from the MDRO network.

BMC infectious diseases·2026
Same author

Association Between Cirrhosis and Acute or Severe Limb Ischemic Events Among Hospitalizations with Peripheral Artery Disease: A National Inpatient Sample Analysis.

Medicina (Kaunas, Lithuania)·2026
Same author

Life-threatening neurotoxicity following off-label ivermectin use in metastatic breast cancer: a case report.

Postgraduate medicine·2026
Same author

Meeting the 2024 UN General Assembly declaration targets on antimicrobial resistance.

Lancet (London, England)·2026
Same author

Efficacy and Safety of Diaphragmatic Breathing Exercises for Gastroesophageal Reflux Disease: A Systematic Review and Meta-Analysis.

Journal of clinical medicine·2026

Related Experiment Video

Updated: Jun 24, 2025

Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients
06:14

Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients

Published on: October 15, 2017

8.3K

Ibrexafungerp: A narrative overview.

L'Emir Wassim El Ayoubi1, Fatima Allaw1, Elie Moussa2

  • 1Division of Infectious Diseases, American University of Beirut Medical Center, Beirut, Lebanon.

Current Research in Microbial Sciences
|June 14, 2024
PubMed
Summary
This summary is machine-generated.

Ibrexafungerp (IBX) is a novel antifungal medication that inhibits fungal cell wall synthesis. It shows efficacy against resistant strains and in clinical trials for various infections, including vulvovaginal candidiasis.

Keywords:
Candida aurisIbrexafungerpInvasive candidiasisInvasive pulmonary aspergillosisVulvovaginal candidiasis

More Related Videos

Author Spotlight: Investigating Islet Abnormalities and Function with a Pseudoislet Protocol
08:04

Author Spotlight: Investigating Islet Abnormalities and Function with a Pseudoislet Protocol

Published on: November 3, 2023

1.9K
Monitoring On-Target Signaling Responses in Larval Zebrafish - Z-REX Unmasks Precise Mechanisms of Electrophilic Drugs and Metabolites
05:28

Monitoring On-Target Signaling Responses in Larval Zebrafish - Z-REX Unmasks Precise Mechanisms of Electrophilic Drugs and Metabolites

Published on: June 2, 2023

800

Related Experiment Videos

Last Updated: Jun 24, 2025

Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients
06:14

Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients

Published on: October 15, 2017

8.3K
Author Spotlight: Investigating Islet Abnormalities and Function with a Pseudoislet Protocol
08:04

Author Spotlight: Investigating Islet Abnormalities and Function with a Pseudoislet Protocol

Published on: November 3, 2023

1.9K
Monitoring On-Target Signaling Responses in Larval Zebrafish - Z-REX Unmasks Precise Mechanisms of Electrophilic Drugs and Metabolites
05:28

Monitoring On-Target Signaling Responses in Larval Zebrafish - Z-REX Unmasks Precise Mechanisms of Electrophilic Drugs and Metabolites

Published on: June 2, 2023

800

Area of Science:

  • Mycology
  • Pharmacology
  • Infectious Diseases

Background:

  • Ibrexafungerp (IBX) is a new antifungal agent targeting fungal cell wall synthesis.
  • It inhibits the β-(1,3)-D-glucan (BDG) synthase enzyme, offering a distinct mechanism from existing antifungals.
  • IBX demonstrates activity against a broad spectrum of fungal pathogens, including resistant strains.

Purpose of the Study:

  • To evaluate the efficacy and safety of ibrexafungerp (IBX) as a novel antifungal agent.
  • To assess IBX's activity against various fungal species, including resistant strains and in preclinical models.
  • To review clinical trial data for IBX in treating candidiasis and aspergillosis.

Main Methods:

  • Review of preclinical data on IBX's mechanism of action, spectrum of activity, and pharmacokinetic properties.
  • Analysis of in vivo studies in murine models of invasive candidiasis (IC) and invasive pulmonary aspergillosis (IPA).
  • Examination of clinical trial results for vulvovaginal candidiasis (VVC), IC, and emerging pathogens like *Candida auris*.

Main Results:

  • IBX exhibits broad-spectrum activity, including against azole- and echinocandin-resistant strains, and possesses anti-biofilm properties.
  • Pharmacokinetic studies show favorable bioavailability and tissue distribution with low drug interaction potential.
  • Clinical trials demonstrate IBX's non-inferiority to fluconazole for VVC treatment and prophylaxis, with promising results in IC and *C. auris* infections.

Conclusions:

  • Ibrexafungerp (IBX) represents a significant advancement in antifungal therapy due to its unique mechanism and broad spectrum of activity.
  • Its efficacy in clinical trials for VVC and promising results in invasive fungal infections warrant its place in the antifungal armamentarium.
  • Further investigation is encouraged for IBX, particularly in complex and refractory fungal infections.